RecruitingPhase 2NCT04117672

Antisecretory Factor In Severe Traumatic Brain Injury

Evaluation of Antisecretory Factor in Treatment of Severe Traumatic Brain Injury With Multimodal Monitoring

Sponsor

Peter Siesjö

Enrollment

20 participants

Start Date

Mar 10, 2020

Study Type

INTERVENTIONAL

Conditions

Traumatic Brain Injury

Summary

This study evaluates the addition of Salovum, an egg yolk powder enriched for antisecretory factor, to standard care of participants with severe traumatic brain injury. Half of the participants will be administered Salovum while the other half will be given a placebo egg yolk powder, not enriched for antisecretory factor. Intracranial pressure (ICP), partial brain oxygen pressure (PtbO2), microdialysis of metabolites and inflammatory mediators and trauma intensity level (TIL) will be assessed in all patients.

Eligibility

Min Age: 10 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo egg yolk powder and Salovum for people with traumatic brain injury. The study is currently recruiting participants at 1 location. People eligible for this study include aged 10 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.